Novo Nordisk reported Phase 3 data showing its combination GLP‑1/amylin candidate, CagriSema, reduced blood glucose and weight more than semaglutide (Wegovy) in a type 2 diabetes population. The topline results cited differences in HbA1c reduction and percent body‑weight loss across enrolled cohorts and estimands used in the analysis, per company statements. Novo emphasized the results as support for regulatory filings in obesity and diabetes and stressed comparative positioning against competitors including Eli Lilly’s offerings. The readout sharpens the commercial race in metabolic drugs and will influence regulatory reviews, payer modeling, and competitive positioning across the GLP‑1/amylin class.